Compass-2026-JPM.pdf

1、Transforming Mental Health CareInvestor PresentationJanuary 20262|Compass PathwaysCautionary Note Regarding Forward-Looking Statements This presentation includes“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995,as amended.In some cases,you can ide

2、ntify forward-looking statements by terms such as“believe,”“continue,”“could,”“estimate,”“expect,”“may,”“might,”“plan,”“potential,”“project,”“target,”“will,”“would,”or the negative of these terms,and similar expressions intended to identify forward-looking statements.However,not all forward-looking

3、statements contain these identifying words.These forward-looking statements include express or implied statements relating to our strategic plans or objectives;our plans and expectations regarding our clinical trials,including our Phase 3 trials in TRD and our planned Phase 2b/3 trial in PTSD;our ex

4、pectations regarding the time periods for the release of data from the COMP005 and COMP006 Phase 3 trials for TRD;our expectations regarding discussions with the FDA regarding potential NDA acceleration strategies,including potential for rolling NDA submission for COMP360 psilocybin treatment in TRD

5、;our expectations regarding potential commercial launch timelines;the potential for the pivotal Phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all;our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment,i

6、ncluding as a treatment for TRD and PTSD;any implication that past results will be predictive of future results;our expectations regarding the benefits of our investigational COMP360 psilocybin treatment;our ability to obtain adequate coverage and reimbursement for our investigational COMP360 psiloc